CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
MASH
CHOLESTASIS
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees
Embassy of Education
Webcasts Abstract Library Committee Members
 
HBV-Single Disease Content  
Featured Article

Webcasts
HBV/HDV-ACT Connect (ADVANCING CURATIVE TREATMENTS)   Educational Webcast
Hepatitis B and D Infection   Educational Webcast
HBV/HDV Hot Topics & Virtual Roundtable   Educational Webcast
HBV, HCV, and HDV   Educational Webcast
 
 
Slide Library
   Released: 2023
Webcast
Stopping All Therapy in HBV Clinical Trials: What Should Be the Criteria for Discontinuation
23 slides
 
 
   Released: 2023
Webcast
New Insights Into The Biology Of HDV: Implications For Drug Development
42 slides
 
 
   Released: 2023
Webcast
HBV Overview of the Last 3 Years For Drug Development: Phase 2 Trials
43 slides
 
 
   Released: 2023
Webcast
Emerging Therapies for HBV in the Next Three Years (Pre-clinical to Phase 1)
31 slides
 
 
   Released: 2023
Webcast
What Are the Most Promising Immunomodulatory Therapies for HBV Infection?
29 slides
 
 
   Released: 2023
Webcast
Emerging Concepts and Data CpAMS Third and Fourth Generation
33 slides
 
 
   Released: 2023
Webcast
Does the New Data on HBV DNA Integration and HBsAg Production Effect the Design and Definition of Treatment Endpoints of Phase II and Phase III Studies?
20 slides
 
 
   Released: 2023
Webcast
Is there a real difference between ETV and TDF/TAF in relapse and HCC?
27 slides
 
 
   Released: 2023
Webcast
How Do We Fit FNA and Liver Biopsy Into HBV Drug Development and Design? Should All Studies Have FNA Subset and Examine Intrahepatic Immune Activity? CccDNA? Integrants?
19 slides
 
 
   Released: 2023
Webcast
Should All Patients With HDV Be Treated?
22 slides
 
 
   Released: 2023
Webcast
HDV Update: Review of the Last 3 Years
18 slides
 
 
   Released: 2023
Webcast
Hepatitis Delta: How Should Bulevirtide Be Used in Clinical Practice
27 slides
 
 
   Released: 2023
Webcast
What Other Therapies Are Being Developed for HDV Infection? NAPS, Lambda, and Lonafarnib
36 slides
 
 
   Released: 2023
Webcast
What Is the Role of Interferon Therapy in HDV?
30 slides
 
 
   Released: 2021
Webcast
HBV Alliance: Expert Recommendations on Managing Patients with Chronic Hepatitis B
56 slides
 
 
   Released: 2021
Webcast
Acute HBV
17 slides
 
 
   Released: 2021
Webcast
Chemotherapy/Reactivation
26 slides
 
 
   Released: 2021
Webcast
Current Management of Chronic Hepatitis B
30 slides
 
 
   Released: 2021
Webcast
Epidemiology of HBV
34 slides
 
 
   Released: 2021
Webcast
Evaluation of the Patient With Chronic HBV
26 slides
 
 
   Released: 2021
Webcast
Everything Old Is New Again!
41 slides
 
 
   Released: 2021
Webcast
Extrahepatic Manifestations of Hepatitis B
34 slides
 
 
   Released: 2021
Webcast
HBsAg Quant HBV Genotyping HBV RNA Quant Where We Are in 2020
41 slides
 
 
   Released: 2021
Webcast
HBV & Hepatitis D (Delta)
26 slides
 
 
   Released: 2021
Webcast
HBV and Liver Cancer
34 slides
 
 
   Released: 2021
Webcast
HBV and NAFLD
35 slides
 
 
   Released: 2021
Webcast
HBV Coinfection With HCV or HIV
35 slides
 
 
   Released: 2021
Webcast
HBV: New Therapies & Clinical Trials
37 slides
 
 
   Released: 2021
Webcast
Hepatitis B Screening: CDC, AASLD, USPSTF
24 slides
 
 
   Released: 2021
Webcast
Hepatitis B: Treatment Endpoints
27 slides
 
 
   Released: 2021
Webcast
Hepatitis B: Update on Treatment Guidelines
27 slides
 
 
   Released: 2021
Webcast
How to Diagnose Hepatitis B
25 slides
 
 
   Released: 2021
Webcast
Immunization for HBV
31 slides
 
 
   Released: 2021
Webcast
Management of HBV: New Data
26 slides
 
 
   Released: 2021
Webcast
Natural History of HBV
39 slides
 
 
   Released: 2021
Webcast
Treatment of Hepatitis B: Controversies 2020
63 slides
 
 
   Released: 2021
Webcast
Update on Hepatitis B
54 slides
 
 
   Released: 2021
Webcast
WHO Hepatitis Elimination Targets
46 slides
 
 
   
     
 
 
 
Abstract Library
1.Updated Guidelines for the Prevention and Management of Chronic Hepatitis B-World Health Organization 2024 Compared With China 2022 HBV Guidelines
 

Viral Hepat. 2024 Dec:31 Suppl 2:13-22. doi: 10.1111/jvh.14032. Epub 2024 Nov 6.

Grace Lai-Hung Wong 1 2
 
2.Hepatitis B virus (HBV) viremia despite tenofovir disoproxil fumarate-containing antiretroviral therapy in persons with HBV/HIV coinfection
 

J Clin Virol. 2024 Dec:175:105733. doi: 10.1016/j.jcv.2024.105733. Epub 2024 Oct 2.

Patrick Ryan 1, Elizabeth Odegard 1, Heidi Meeds 1, Margaret Lartey 2, Vincent J Ganu 3, Kenneth Tachi 2, Hongmei Yang 4, Oluwayemisi Ojewale 5, Isaac Boamah 6, Adjoa Obo-Akwa 7, Kenneth Antwi 3, Peter L Anderson 8, Jason T Blackard 1, Awewura Kwara 9
 
3.HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal
 

J Infect Dis. 2024 Oct 30:jiae541. doi: 10.1093/infdis/jiae541. Online ahead of print.

Norah A Terrault 1, Richard Sterling 2, Anna S Lok 3, Marc G Ghany 4, Jordan J Feld 5, Gavin Cloherty 6, Abdus S Wahed 7, Xue Yang 8
 
4.What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis
 

Liver Int. 2024 Nov;44(11):2890-2903. doi: 10.1111/liv.16064. Epub 2024 Aug 29.

Ciro Celsa 1 2, Giacomo E M Rizzo 1 3 4, Gabriele Di Maria 5, Marco Enea 5, Marco Vaccaro 6, Gabriele Rancatore 1 4, Pietro Graceffa 1, Giuseppe Falco 1, Salvatore Petta 1, Giuseppe Cabibbo 1, Vincenza Calvaruso 1, Antonio Craxì 1, Calogero Cammà 1, Vito Di Marco 1
 
5.Characterization of Individuals With Hepatitis B Virus-Related Cirrhosis in a Large Integrated Health Care Organization, 2008-2019
 

JPublicHealthManagPract. 2024NovDec;30(6):E270E281.doi:10.1097/PHH.0000000000002001. Epub 2024 Jun 13.

Ana Florea 1, Katherine J Pak, Prabhu Gounder, Debbie E Malden, Theresa M Im, Amit S Chitnis, Robert J Wong, Amandeep K Sahota, Sara Y Tartof
 
6.Impaired HBsAg release and antiproliferative/antioxidant cell regulation by HBeAg-negative patient isolates reflects an evolutionary process
 

Liver Int. 2024 Oct;44(10):2773-2792. doi: 10.1111/liv.16048. Epub 2024 Jul 30.

Michael Basic 1 2, Keerthihan Thiyagarajah 1 2, Mirco Glitscher 2, Anja Schollmeier 2, Qingyan Wu 2, Esra Görgülü 1 2, Pia Lembeck 2 3, Jannik Sonnenberg 3, Julia Dietz 1, Fabian Finkelmeier 1, Michael Praktiknjo 3, Jonel Trebicka 3, Stefan Zeuzem 1, Christoph Sarrazin 1 4, Eberhard Hildt 2 5, Kai-Henrik Peiffer 1 2 3
 
7.HBV shows different levels of adaptation to HLA class I-associated selection pressure correlating with markers of replication
 

J Hepatol. 2024 Nov 11:S0168-8278(24)02705-3. doi: 10.1016/j.jhep.2024.10.047.Online ahead of print.

Tatjana Schwarz 1, Johannes Ptok 1, Maximilian Damagnez 1, Christopher Menne 1, Elahe Salimi Alizei 2, Julia Lang-Meli 2, Michelle Maas 2, Daniel Habermann 3, Daniel Hoffmann 3, Julian Schulze Zur Wiesch 4, Georg Lauer 5, Helenie Kefalakes 6, Markus Cornberg 6, Anke Rm Kraft 6, Smaranda Gliga 7, Hans H Bock 7, Peter A Horn 8, Mala K Maini 9, Robert Thimme 2, Heiner Wedemeyer 6, Jacob Nattermann 10, Falko M Heinemann 8, Tom Luedde 7, Christoph Neumann-Haefelin 2, Andreas Walker 1, Jörg Timm 11
 
8.HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal
 

J Infect Dis. 2024 Oct 30:jiae541. doi: 10.1093/infdis/jiae541. Online ahead of print.

Norah A Terrault 1, Richard Sterling 2, Anna S Lok 3, Marc G Ghany 4, Jordan J Feld 5, Gavin Cloherty 6, Abdus S Wahed 7, Xue Yang 8
 
9.What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis
 

Liver Int. 2024 Nov;44(11):2890-2903. doi: 10.1111/liv.16064. Epub 2024 Aug 29.

Ciro Celsa 1 2, Giacomo E M Rizzo 1 3 4, Gabriele Di Maria 5, Marco Enea 5, Marco Vaccaro 6, Gabriele Rancatore 1 4, Pietro Graceffa 1, Giuseppe Falco 1, Salvatore Petta 1, Giuseppe Cabibbo 1, Vincenza Calvaruso 1, Antonio Craxì 1, Calogero Cammà 1, Vito Di Marco 1
 
10.Estimating Prevalence and Number of People With Chronic Hepatitis B: A Multiplier Method Based on Public Health Surveillance Data in UK (2015-2021)
 

J Viral Hepat. 2024 Oct 16. doi: 10.1111/jvh.14019. Online ahead of print.

Ruth Simmons 1 2, Ross Harris 1, Aaron G Lim 2 3, David Leeman 1, Mary E Ramsay 1, Matthew Hickman 2 3, Sema Mandal 1 2
 
11.Characterization of Individuals With Hepatitis B Virus-Related Cirrhosis in a Large Integrated Health Care Organization, 2008-2019
 

JPublicHealthManagPract. 2024NovDec;30(6):E270E281.doi:10.1097/PHH.0000000000002001. Epub 2024 Jun 13.

Ana Florea 1, Katherine J Pak, Prabhu Gounder, Debbie E Malden, Theresa M Im, Amit S Chitnis, Robert J Wong, Amandeep K Sahota, Sara Y Tartof
 
12.Impaired HBsAg release and antiproliferative/antioxidant cell regulation by HBeAg-negative patient isolates reflects an evolutionary process
 

Liver Int. 2024 Oct;44(10):2773-2792. doi: 10.1111/liv.16048. Epub 2024 Jul 30.

Michael Basic 1 2, Keerthihan Thiyagarajah 1 2, Mirco Glitscher 2, Anja Schollmeier 2, Qingyan Wu 2, Esra Görgülü 1 2, Pia Lembeck 2 3, Jannik Sonnenberg 3, Julia Dietz 1, Fabian Finkelmeier 1, Michael Praktiknjo 3, Jonel Trebicka 3, Stefan Zeuzem 1, Christoph Sarrazin 1 4, Eberhard Hildt 2 5, Kai-Henrik Peiffer 1 2 3
 
13.Empowering Pharmacy Technicians as Vaccine Champions: A Pilot Study in Independent Community Pharmacies
 

J Am Pharm Assoc (2003). 2024 Sep 23:102257. doi: 10.1016/j.japh.2024.102257.Online ahead of print.

Allison Hursman 1, Hailey Wanner 2, Ellen Rubinstein 3
 
14.A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir
 

J Clin Virol. 2024 Oct:174:105711. doi: 10.1016/j.jcv.2024.105711. Epub 2024 Jun 28.

Sheila F Lumley 1, Marion Delphin 2, Jolynne F Mokaya 3, Cedric C S Tan 2, Emily Martyn 2, Motswedi Anderson 4, Ka Chun Li 2, Elizabeth Waddilove 2, Gloria Sukali 5, Louise O Downs 6, Khadija Said 2, Dorcas Okanda 7, Cori Campbell 8, Eli Harriss 9, Yusuke Shimakawa 10, Philippa C Matthews 11
 
15.Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders
 

Clin Infect Dis. 2024 Aug 16;79(2):562-563. doi: 10.1093/cid/ciae320.

Rachel K Russ 1, Haley M Vandehei 2, Maria I Golovkina 1, Harshitha Mogallapalli 3, Freddy Caldera 3, Mary S Hayney 1
 
16.Unmet needs in the clinical management of chronic hepatitis B infection
 

JFormosMedAssoc. 2024Aug17:S09296646(24)003887.doi:10.1016/j.jfma.2024.08.020. Online ahead of print.

Peter D Block 1, Joseph K Lim 2
 
17.Hepatitis B Virus Treatment in :Children Common Challenges and Management Options in a Case-Based Format
 

J Pediatric Infect Dis Soc. 2024 Aug 22:piae084. doi: 10.1093/jpids/piae084.Online ahead of print.

Naseem Ravanbakhsh 1, Andres Rivera Campana 1, Catherine Chapin 1 2, Ravi Jhaveri 3 2

 
 
18.Unmet needs in the clinical management of chronic hepatitis B infection
 

JFormosMedAssoc. 2024Aug17:S09296646(24)003887.doi:10.1016/j.jfma.2024.08.020. Online ahead of print.

Peter D Block 1, Joseph K Lim 2
 
19.Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Non responders
 

Clin Infect Dis.?2024 Aug 16;79(2):562-563.?doi: 10.1093/cid/ciae320. 

Rachel K Russ?1,?Haley M Vandehei?2,?Maria I Golovkina?1,?Harshitha Mogallapalli?3,?Freddy Caldera?3,?Mary S Hayney?1 
 
20.Progress Toward Elimination of Mother-to-Child Transmission of Hepatitis B Virus - Region of the Americas, 2012-2022
 

MMWR Morb Mortal Wkly Rep. 2024 Jul 25;73(29):648-655. doi: 10.15585/mmwr.mm7329a3.

Mary M Alleman, Leandro Soares Sereno, Alvaro Whittembury, Xi Li, Marcela Contreras, Carmelita Pacis-Tirso, Martha Velandia Gonzalez, Karen Broome, Sandra Jones, Daniel Salas, Monica Alonso, Rania A Tohme, Annemarie Wasley
 
21.To B or not to B: how the hepatitis B surveillance case definition can misdirect public health actions
 

Commun Dis Intell (2018). 2024 Jul 17:48. doi: 10.33321/cdi.2024.48.39.

Anna B Pierce 1 2 3 4, Simon Crouch 1 3, Edura Jalil 1 3, Adrian Alexander 4, Joe Sasadeusz 5 6, Victor Au Yeung 1 3 7, Aswan Tai 1, Rhonda L Stuart 2 3 8
 
22.Screening rates for hepatitis B and C among low-income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study
 

J Viral Hepat. 2024 Jul 10. doi: 10.1111/jvh.13981. Online ahead of print.

Hind A Beydoun 1 2, Jack Tsai 1 2
 
23.High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
 

Liver Int. 2024 Jul 15. doi: 10.1111/liv.16029. Online ahead of print.

Simon J Hume 1 2 3, Danny K Wong 4, Man-Fung Yuen 4, Kathy Jackson 3, Sara Bonanzinga 3, Sara Vogrin 2, Samuel A L Hall 1 2, Gareth S Burns 5, Paul V Desmond 1, Vijaya Sundararajan 1 2, Dilip Ratnam 6, Miriam T Levy 7, John S Lubel 8, Amanda J Nicoll 9, Simone I Strasser 10, William Sievert 6, Meng C Ngu 11, Marie Sinclair 12, Christopher Meredith 13, Gail Matthews 14, Peter A Revill 3, Margaret Littlejohn 3, Scott Bowden 3, Kumar Visvanathan 1 2, Jacinta A Holmes 1 2, Alexander J Thompson 1 2
 
24.Hepatitis B infection and immunity in Migrant Children and Pregnant Persons in Europe: A Systematic Review and Meta-Analysis
 

J Travel Med. 2024 Jul 11:taae094. doi: 10.1093/jtm/taae094. Online ahead of print.

Carla Hobart 1, Julia M Pescarini 1 2, Laith Evans 2, Haleema S Adil 3, Shehzhore T Adil 3, Anna Deal 4, Jessica Carter 4, Philippa C Matthews 5 6 7, Sally Hargreaves 4, Nuria Sanchez Clemente 1 2 4
 
25.Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and outcome
 

J Hepatol. 2024 Jul 4:S0168-8278(24)02343-2. doi: 10.1016/j.jhep.2024.06.037.Online ahead of print.

Fabien Zoulim 1, Pei-Jer Chen 2, Maura Dandri 3, Patrick Kennedy 4, Christoph Seeger 5
 
View More
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

MASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.